Innovation Pharmaceuticals Inc (IPIX)

[Michel]

"The OMS advises against the use of remdesivir for COVID-19 because there is no evidence that it improves patient survival
The institution concludes after reviewing 7,000 cases that Gilead's antiviral, authorized against the coronavirus in the US and the EU, does not have "significant effects on mortality or other relevant outcomes such as the need for mechanical ventilation."...